Treatment of Skin Cancer with a Selective Apoptotic-Inducing CuradermBEC5 Topical Cream Containing Solasodine Rhamnosides


Solasodine rhamnosides produced in plants as secondary metabolites, are safe and effective when treating a variety of cancers, including non-melanoma skin cancers. They are cytotoxic against multi-drug resistant tumor cells, stimulate lasting immunity against cancer, are not mutagenic and display anti-mutagenic properties. These antineoplastics, through cellular specific receptor-mediated actions, directly induce apoptosis by triggering extrinsic and intrinsic apoptotic pathways in cancer cells but not normal cells. CuradermBEC5 contains solasodine rhamnosides and is a topical formulation for the treatment of keratoses and non-melanoma skin cancers. The mode of action, together with the selectivity towards cancer cells, with CuradermBEC5 therapy, results in outstanding beneficial outcomes. This study shows graphically and pictorially that CuradermBEC5 seeks and destroys basal cell carcinoma whilst normal skin cells replace the dead cancer cells during therapy, emanating into impressive cosmetic end results. The clinical observations with CuradermBEC5 therapy reveal that initially the lesion size increases over four-fold due to the interaction of CuradermBEC5 with deeper and more lateral tumor cells, followed by a decrease in size, ultimately, resulting in complete elimination of the basal cell carcinoma.

Share and Cite:

Cham, A. and Cham, B. (2015) Treatment of Skin Cancer with a Selective Apoptotic-Inducing CuradermBEC5 Topical Cream Containing Solasodine Rhamnosides. International Journal of Clinical Medicine, 6, 326-333. doi: 10.4236/ijcm.2015.65042.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Stern, R.S. (2010) Prevalence of a History of Skin Cancer in 2007: Results of an Incidence-Based Model. Archives of Dermatology, 146, 279-282.
[2] American Cancer Society (2015) Cancer Facts & Figures.
[3] The Lewen Group, Inc. (2005) The Burden of Skin Diseases 2005. The Society for Investigative Dermatology and The American Academy of Dermatology Association.
[4] Criscione, V.D., Weinstock, M.A., Naylor, M.F., Luque, C., Elde, M.J. and Bingham, S.F. (2009) Actinic Keratoses Natural History and Risk of Malignant Transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer, 115, 2523-2530.
[5] Robinson, J.K. (2005) Sun Exposure, Sun Protection and Vitamin D. JAMA, 294, 1541-1543.
[6] Sun Protection. Cancer Trends Progress Report—2009/2010 Update. National Cancer Institute.
[7] Mohan, S.V. and Chang, A.L.S. (2014) Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations. Current Dermatology Reports, 3, 40-45.
[8] Karia, P.S., Han, J. and Schmults, C.D. (2013) Cutaneous Squamous Cell Carcinoma: Estimated Incidence of Disease, Nodal Metastasis, and Death from Disease in the United States, 2012. Journal of the American Academy of Dermatology, 68, 957-966.
[9] Hartevelt, M.M., Bavink, J.N., Kootte, A.M., Vermeri, B.J. and Vandenbroucke, J.P. (1990) Incidence of Skin Cancer after Renal Transplantation in The Netherlands. Transplantation, 49, 506-509.
[10] Karagas, M.R., Greenberg, E.R., Spencer, S.K., Stukel, T.A. and Mott, L.A., New Hampshire Skin Cancer Study Group (1999) Increase in Incidence Rates of Basal Cell and Squamous Cell Skin Cancer in New Hampshire, USA. International Journal of Cancer, 81, 555-559.<555::AID-IJC9>3.0.CO;2-R
[11] Cham, B.E. (2011) Topical Solasodine Rhamnosyl Glycosides Derived from the Eggplant Treats Large Skin Cancers: Two Case Reports. International Journal of Clinical Medicine, 2, 473-477.
[12] Cham, B.E. (2011) Topical CuradermBEC5 Therapy for Periocular Nonmelanoma Skin Cancers: A Review of Clinical Outcomes. International Journal of Clinical Medicine, 4, 233-238.
[13] Guy, G.P., Machlin, S.R., Ekurieme, D.U. and Yabroff, K.R. (2014) Prevalence and Costs of Skin Cancer Treatment in the US, 2002-2006 and 2007-2011. American Journal of Preventive Medicine, 104, e69-e74.
[14] Cham, B.E. and Daunter, B. (1990) Topical Treatment for Pre-Malignant and Malignant Skin Cancers with Curaderm. Drugs of Today, 26, 55-58.
[15] Cham, B.E., Daunter, B. and Evans, R. (1991) Topical Treatment of Malignant and Premalignant Skin Cancers by Very Low Concentrations of a Standard Mixture of Solasodine Glycosides. Cancer Letters, 59, 183-192.
[16] Daunter, B. and Cham, B.E. (1990) Solasodine Glycosides. In Vitro Preferential Cytotoxicity for Human Cancer Cells. Cancer Letters, 55, 209-220.
[17] Cham, B.E. (2013) Drug Therapy: Solamargine and Other Solasodine Rhamnosyl Glycosides as Anticancer Agents. Modern Chemotherapy, 2, 33-49.
[18] Cham, B.E. and Chase, T.R. (2012) Solasodine Rhamnosyl Glycosides Cause Apoptosis in Cancer Cells. Do They Also Prime the Immune System Resulting in Long-Term Protection Against Cancer? Planta Medica, 78, 349-353.
[19] Kuo, K.W., Hsu, S.H., Li, Y.P., Lin, W.L., Liu, L.F., Chang, L.C., Lin, C.C., Lin, C.N. and Sheu, H.M. (2000) Anticancer Activity Evaluation of the Solanum Glycoalkaloid Solamargine: Triggering Apoptosis in Human Hepatoma Cells. Biochemical Pharmacology, 60, 1865-1873.
[20] Liang, C.H., Liu, L.F., Shiu, L.Y., Huang, Y.S., Chang, L.C. and Kuo, K.W. (2004) Action of Solamargine on TNFs and Cisplatin-Resistant Human Lung Cancer Cells. Biochemical and Biophysical Research Communications, 322, 751-758.
[21] Wang, Y., Gao, J., Gu, G., Li, G., Cui, C., Sun, B. and Lou, H. (2011) In Situ RBL Receptor Visualization and Its Mediated Anticancer Activity for Solasodine Rhamnosides. ChemBioChem, 12, 2418-2420.
[22] Goldberg, L.H., Landau, J.M., Moody, M.N. and Vergilis-Kalner, I.J. (2011) Treatment of Bowen’s Disease on the Penis with Low Concentration of a Standard Mixture of Solasodine Glycosides and Liquid Nitrogen. Dermatologic Surgery, 37, 858-861.
[23] Cham, B.E. (2013) Inspired by Nature, Proven by Science: The New Generation Cancer Treatment That Causes Cancer Cells to Commit Suicide. Colorite Graphics, Vanuatu.
[24] Punjabi, S., Cook, L.J., Kersey, P., Marks, R. and Cerio, R. (2008) Solasodine Glycoalkaloids: A Novel Topical Therapy for Basal Cell Carcinoma: A Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicentre Study. International Journal of Dermatology, 47, 78-82.
[25] Lipscombe, R.J., Carter, S.J. and Ruane, M. (2005) Rhamnose Binding Protein. United States Patent 6, 930, 171 B2.
[26] Shiu, L.Y., Chang, L.C., Liang, C.H., Huang, Y.S., Sheu, H.M. and Kuo, K.W. (2007) Solamargine Induces Apoptosis and Sensitizes Breast Cancer Cells to Cisplatin. Food and Chemical Toxicology, 45, 2155-2164.
[27] Liang, C.H., Shiu, L.Y., Chang, L.C., Sheu, H.M. and Kuo, K.W. (2007) Solamargine Upregulation of Fas, Downregulation of HER2, and Enhancement of Cytotoxicity Using Epirubicin in NSCLC Cells. Molecular Nutrition & Food Research, 51, 999-1005.
[28] Shiu, L.Y., Liang, C.H., Chang, L.C., Sheu, H.M., Tsai, E.M. and Kuo, K.W. (2009) Solamargine Induces Apoptosis and Enhances Susceptibility to Trastazumab and Epirubicin in Breast Cancer Cells with Low or High Expression Levels of HER2/Neu. Bioscience Reports, 29, 35-45.
[29] Sun, L.M., Zhao, Y., Li, X., Yuan, H.Q., Cheng, A.X. and Lou, H.X. (2010) A Lysosomal-Mitochondrial Death Pathway Is Induced by Solamargine in Human K562 Leukemia Cells. Toxicology in Vitro, 24, 1504-1511.
[30] Sun, L.M., Zhao, Y., Yuan, H.Q., Li, X., Cheng, A.X. and Lou, H.X. (2010) Solamargine, a Steroidal Alkaloid Glycoside, Induces Oncosis in Human K562 Leukemia and Squamous Cell Carcinoma KB Cells. Cancer Chemotherapy and Pharmacology, 65, 1125-1130.
[31] Li, X., Zhao, Y., Wu, W.K.K., Liu, S.S., Cui, M. and Lou, H.X. (2011) Solamargine Induces Apoptosis Associated with p53 Transcription-Dependent and Transcription-Independent Pathways in Human Osteosarcoma U20S Cells. Life Sciences, 88, 314-321.
[32] Liu, L.F., Liang, C.H., Shiu, L.Y., Lin, W.L., Lin, C.C. and Kuo, K.W. (2004) Action of Solamargine on Human Lung Cancer Cells—Enhancement of the Susceptibility of Cancer Cells to TNFs. FEBS Letters, 577, 67-74.
[33] Cham, B.E. (2015) CuradermBEC5 Natural, Non-Invasive Medication for Skin Cancer, Biopsy and 5 Year Cancer-Free Criteria. 2nd Edition, Curaderm Global Ltd., Vanuatu.
[34] Cham, B.E. (2007) Solasodine Rhamnosyl Glycosides in a Cream Formulation Is Effective for Treating Large and Troublesome Skin Cancers. Research Journal of Biological Sciences, 2, 749-761.
[35] Cham, B.E. (2007) Solasodine Rhamnosyl Glycosides Specifically Bind Cancer Cell Receptors and Induce Apoptosis and Necrosis. Treatment for Skin Cancer and Hope for Internal Cancers. Research Journal of Biological Sciences, 2, 503-514.
[36] Cham, B.E. and Meares, H.M. (1987) Glycoalkaloids from Solanum sodomaeum L. Are Effective in the Treatment of Skin Cancers in Man. Cancer Letters, 36, 111-118.
[37] Cham, B.E. (1994) Solasodine Glycosides as Anti-Cancer Agents: Pre-Clinical and Clinical Studies. Asia Pacific Journal of Pharmacology, 9, 113-118.
[38] CNN Money (2010) Tanning Salons Burned by Health Care Bill.
[39] Cham, A., Cham, K.E., Chase, T. and Cham, B.E. (2015) A Standardized Plant Extract Containing a Target Compound Is Acceptable as a Potent Therapeutic Entity. Relevance to BEC and Solamargine, Example of a Topical Clinical Formulation CuradermBEC5. Journal of Cancer Research and Treatment, 3, 22-27.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.